Organizations Urge Lawmakers to Advance PASTEUR Act Before Congress Ends

Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic

WASHINGTON—Organizations representing health care providers, public health professionals, scientists, patients, and the biotech and diagnostics industries today issued the following statement, calling on lawmakers to advance the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act before the 117th Congress ends on Jan. 3, 2023:

“With its power to jump-start the development of desperately needed antimicrobials, the PASTEUR Act is a vital next step in the global fight to address the increasing threat of antimicrobial resistance.

“Yet although this bipartisan, bicameral, patients-first bill has ignited conversations about the importance of addressing antimicrobial resistance, it has not been signed into law.

“Antimicrobial resistance is one of the greatest public health threats of our time. Without swift action, the global death toll could reach a staggering 10 million by 2050.

“Individuals with underlying health conditions may be more susceptible to drug-resistant infections, but because resistant infections have been increasing, every American—and every global citizen—is in jeopardy of contracting a drug-resistant infection for which current therapeutics are insufficient.

“We believe that the PASTEUR Act would transform the broken antimicrobial pipeline by delivering the novel, medically significant therapeutics that patients desperately need to stave off lethal infections—and avert a devastating pandemic.

“PASTEUR would also safeguard U.S. investment in antibiotic development by funding antimicrobial stewardship programs that guide optimal antibiotic use and preserve antibiotics’ efficacy.

“The time for action is now. Delays in passing the PASTEUR Act are delays in developing novel antimicrobials to treat highly resistant, life-threatening infections. And these are delays that many patients—including those who are particularly susceptible to infections, such as those who have cystic fibrosis or cancer, or have received organ transplants—cannot afford.

“Our diverse group of stakeholders is united behind PASTEUR. We urge Congress to enact the PASTEUR Act and invigorate a new era of antimicrobial research and development to avoid another devastating pandemic.”

Signed,

Biotechnology Innovation Organization
Cystic Fibrosis Foundation
Infectious Diseases Society of America
Partnership to Fight Infectious Disease
The Pew Charitable Trusts

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.